LPA RECEPTOR ANTAGONISTS AND USES THEREOF

The application relates to pyrazole derivatives of the general Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The compounds are useful for the treatment of diseases and conditions including fibrosis and liver diseases such as non-alcohol steatohepa...

Full description

Saved in:
Bibliographic Details
Main Authors BESTVATER, Brian P, KAPLAN, Joshua A, ZAGORSKA, Anna, YANG, Kin S, NEUBIG, Megan E
Format Patent
LanguageEnglish
French
Published 17.11.2022
Subjects
CHEMISTRY
HETEROCYCLIC COMPOUNDS
HUMAN NECESSITIES
HYGIENE
MEDICAL OR VETERINARY SCIENCE
METALLURGY
ORGANIC CHEMISTRY
PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS ORMEDICINAL PREPARATIONS
Online AccessGet full text

Cover

More Information
Summary:The application relates to pyrazole derivatives of the general Formula (I) that bind to Lysophosphatidic Acid Receptor 1 (LPAR1) and act as antagonists of LPAR1. The compounds are useful for the treatment of diseases and conditions including fibrosis and liver diseases such as non-alcohol steatohepatitis (NASH), interstitial lung disease (ILD), or chronic kidney disease (CKD). L'invention concerne des dérivés de pyrazole de formule générale (I) qui se lient au récepteur 1 de l'acide lysophosphatidique (LPAR1) et agissent en tant qu'antagonistes de LPAR1. Les composés sont utiles pour le traitement de maladies et d'états notamment la fibrose et des maladies hépatiques telles que la stéatohépatite non alcoolique (NASH), la maladie pulmonaire interstitielle (ILD), ou la maladie rénale chronique (CKD).
Bibliography:Application Number: WO2022US28597